Application of Targeted Mass Spectrometry Imaging in the Pharmaceutical Industry
Within the pharmaceutical industry, the prevailing drive for potent, targeted compounds has driven the need for the confirmation of drug delivery to the target. While overall mass spectrometric instrumentation has delivered ever greater sensitivity and precision, to achieve the absolute greatest sensitivity requires the use of QqQ instruments.
To date, there is no commercially available, MALDI-based, targeted imaging platform. AbbVie has worked together with both MassTech and Agilent to provide a robust, rapid, and most importantly sensitive Atmospheric Pressure Matrix-Assisted Laser Desorption/Ionization Triple Quadrupole platform for the targeted analysis of known compounds of interest, providing up to 200-fold greater sensitivity in comparison to on-market broad-spectrum MALDI instruments.
Presenter: Andrew Bowman (AbbVie, Inc.)
Andrew Bowman is a drug metabolism and disposition scientist in the Quantitative, Translational, and ADME Sciences department of AbbVie, Inc. His focus has been on the development of new and targeted mass spectrometry imaging platforms and their use in the analysis of drugs in tissue. Andrew is a graduate of the doctoral program from Maastricht University’s “Maastricht MultiModal Molecular Imaging Institute (M4I)”, where he focused on the detection and analysis of lipids in MSI.
